Cargando…

Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials

BACKGROUND: We sought to compare cardiovascular outcomes, renal function, and diuresis in patients receiving standard diuretic therapy for acute heart failure (AHF) with or without the addition of SGLT2i. METHODS AND RESULTS: Systematic search of three electronic databases identified nine eligible r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carvalho, Pedro E. P., Veiga, Thiago M. A., Simões e Silva, Ana C., Gewehr, Douglas M., Dagostin, Caroline S., Fernandes, Amanda, Nasi, Guilherme, Cardoso, Rhanderson
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807098/ https://www.ncbi.nlm.nih.gov/pubmed/36592186 http://dx.doi.org/10.1007/s00392-022-02148-2

Ejemplares similares

SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis
por: Cardoso, Rhanderson, et al.
Publicado: (2021)

Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction
por: Fernandes, Amanda D.F., et al.
Publicado: (2021)

The AHA/ACC/HFSA 2022 Heart Failure Guidelines: Changing the Focus to Heart Failure Prevention
por: Abovich, Arielle, et al.
Publicado: (2023)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
por: Ji, Peng‐juan, et al.
Publicado: (2023)

Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
por: Lee, Mei-Chuan, et al.
Publicado: (2022)

Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Qiu, Mei, et al.
Publicado: (2021)

Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
por: Pitt, Bertram, et al.
Publicado: (2022)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
por: Frąk, Weronika, et al.
Publicado: (2023)

Anticoagulantes Orais Diretos Ininterruptos em Ablação por Cateter de Fibrilação Atrial: Pronto para a Prática Clínica
por: Cardoso, Rhanderson, et al.
Publicado: (2020)

Reversibility of High-Grade Atrioventricular Block with Revascularization in Coronary Artery Disease without Infarction: A Literature Review
por: Cardoso, Rhanderson, et al.
Publicado: (2016)

The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives
por: Barreto, Joaquim, et al.
Publicado: (2023)

SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
por: Talha, Khawaja M., et al.
Publicado: (2023)

Alterações no Perfil dos Pacientes atendidos no Pronto Socorro durante o Surto de COVID-19 em um Hospital Geral Especializado em Tratamento Cardiovascular no Brasil
por: Jardim, Thiago Veiga, et al.
Publicado: (2021)

Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
por: Benham, Jamie L., et al.
Publicado: (2021)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

SGLT1: A Potential Drug Target for Cardiovascular Disease
por: Zhao, Mengnan, et al.
Publicado: (2023)

Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease
por: Shao, Shih-Chieh, et al.
Publicado: (2021)

Hydrotherapy in Heart Failure: A Case Report
por: Carvalho, Vitor Oliveira, et al.
Publicado: (2009)

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers
por: Gessner, Arne, et al.
Publicado: (2022)

Precipitation of Euglycemic DKA (euDKA) From the Initiation of SGLT2 Inhibitor (SGLT2i) and 0-Carb Diet Inpatient
por: Popli, Rakesh, et al.
Publicado: (2021)

Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
por: Gomez-Peralta, Fernando, et al.
Publicado: (2017)

Timing of SGLT2i initiation after acute myocardial infarction
por: von Lewinski, Dirk, et al.
Publicado: (2023)

Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes
por: Gronda, Edoardo G., et al.
Publicado: (2022)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure
por: Berezin, Alexander A., et al.
Publicado: (2022)

SGLT2 and cancer
por: Wright, Ernest M.
Publicado: (2020)

Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
por: Rabizadeh, Soghra, et al.
Publicado: (2019)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
por: Suzuki, Yuta, et al.
Publicado: (2022)

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors
por: Vargas-Delgado, Ariana P., et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis
por: Hendryx, Michael, et al.
Publicado: (2022)

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
por: McGovern, Andrew P, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy
por: Aldhaeefi, Mohammed, et al.
Publicado: (2023)

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
por: Inzucchi, Silvio E, et al.
Publicado: (2015)

Reproducibility of the Self-Controlled Six-Minute Walking Test in Heart Failure Patients
por: Guimarães, Guilherme Veiga, et al.
Publicado: (2008)

LBODP046 Reduction In "Cardiovascular Death Or Hospitalisation For Heart Failure" With Sglt-2is Is Dependent On Weight Reduction: A Meta-regression Analysis
por: Ghosal, Samit, et al.
Publicado: (2022)

Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis
por: Rivera, Frederick Berro, et al.
Publicado: (2023)

Erratum to: Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
por: Gomez-Peralta, Fernando, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2cae951tr91aipkpe16ce0mf7a